Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 1:25PM CDT
Astellas Pharma Inc. (ALPMY) announced positive results from a phase IIIb study on Myrbetriq-VESIcare add-on therapy in incontinent overactive bladder patients.
ACT: 295.76 (-0.84), VRX: 225.43 (+0.80)
Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT
MDVN: 125.90 (+3.00), JNJ: 103.42 (+1.12)
Vical Q1 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:24PM CDT
Vical Incorporated (VICL) posted a narrower-than-expected loss of 4 cents per share in the first quarter of 2015 driven by a year-over-year surge in revenues.
VICL: 0.92 (-0.01), ILMN: 200.76 (+1.69), HSP: 88.25 (+0.15)
Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 08, 2:00PM CDT
Medivation's (MDVN) first quarter results were disappointing with the company missing on both the top and the bottom-lines.
MDVN: 125.90 (+3.00), GILD: 111.00 (+1.70), OSIR: 17.78 (+0.49)
Astellas and Potenza Therapeutics team up in cancer R&D
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:54AM CDT
Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 127.23 (+3.40), VRX: 225.43 (+0.80)
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 6.26 (+0.30), PFE: 33.98 (-0.01)
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 6.26 (+0.30), MDVN: 125.90 (+3.00), LCI: 54.86 (+2.26)
Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT
MDVN: 125.90 (+3.00)
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 3:17PM CDT
Vical (VICL) expanded its infectious disease portfolio by acquiring Astellas' (ALPMY) antifungal candidate, ASP2397.
LCI: 54.86 (+2.26), VICL: 0.92 (-0.01), CBM: 40.70 (+1.70)
Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 2:20PM CDT
Medivation, Inc. (MDVN) and Astellas Pharma jointly announced new data from a randomized, double-blind phase II study (TERRAIN) on Xtandi.
CYTK: 6.26 (+0.30), MDVN: 125.90 (+3.00), AZN: 68.74 (-0.55)
Xtandi beats bicalutamide in Phase 2 CRPC trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:28AM CDT
MDVN: 125.90 (+3.00)
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 5:12PM CDT
Amgen (AMGN) submits regulatory application for its cholesterol-lowering candidate, Repatha, in Japan.
LCI: 54.86 (+2.26), CBM: 40.70 (+1.70), AMGN: 163.44 (+1.08)
Best One-Drug Wonder Stock for 2015
Brian Orelli, Keith Speights, and George Budwell, The Motley Fool - Motley Fool - Sun Mar 22, 6:01AM CDT
If a biotech wants to become the next drugmaker with multiple blockbusters on the market, it has to start at the bottom with a single drug. We asked our biotech experts for their top picks for companies with just a single drug on the market. Read...
MDVN: 125.90 (+3.00), OREX: 4.98 (-0.03), ISIS: 64.33 (+1.78)
Amgen JV submits regulatory application in Japan for cholesterol med
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:59AM CDT
AMGN: 163.44 (+1.08)
United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:40PM CDT
United Therapeutics' (UTHR) cancer drug Unituxin gained FDA approval plus a priority review voucher for the treatment of pediatric patients suffering from high-risk neuroblastoma.
LCI: 54.86 (+2.26), UTHR: 179.30 (+6.55), SLXP: 172.96 (+0.15)
Astellas' Cresemba Gains FDA Approval, Under Review in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 3:44PM CDT
Astellas Pharma, Inc.'s (ALPMY) Cresemba gained FDA approval for invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
LCI: 54.86 (+2.26), ECYT: 6.15 (+0.13), SLXP: 172.96 (+0.15)
Ironwood Commences Dosing in Phase I Study on IW-1973 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 4:55PM CST
Ironwood (IRWD) initiates phase I study of its soluble guanylate cyclase (sGC) stimulator, IW-1973.
LCI: 54.86 (+2.26), ACT: 295.76 (-0.84), IRWD: 14.30 (+0.02)
FDA clears Astellas antifungal drug
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 1:46PM CST
Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 9:20AM CST
Medivation (MDVN) beats on both fourth quarter 2014 earnings and revenues; Xtandi sales rise.
MDVN: 125.90 (+3.00), BMRN: 126.02 (+3.24), CBM: 40.70 (+1.70)